drugset / Trial / NCT05835609
PM534 Administered Intravenously to Patients With Advanced Solid Tumors
NaSequentialOpen-labelTreatment
Summary
The goals of this trial are to identify the dose limiting toxicities, to determine the maximum tolerated dose and the recommended dose of PM534 in patients with advanced solid tumors. All Patients will receive PM534 via intravenous.
Timeline
- Start
- 2022-12-23
- Primary completion
- 2026-10
- Completion
- 2026-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PM534 | Unknown | — | Intravenous |
Indications
No indication recorded.